Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies.
We evaluated the suitability of the Friend Virus (FV) model for the development of improved adenovirus vectors for anti-retroviral vaccination using two types of adenovirus vectors, encoding F-MuLV Env and Gag, which differed only in their fiber genes (Ad5 and Ad5F35). Genetically FV-resistant C57BL/6 mice and highly susceptible CB6F1 hybrid mice were vaccinated by either homologous or heterologous prime-boost regimen. After FV challenge, viral loads in the spleens of C57BL/6 mice were reduced approximately 250-fold and were below the detection threshold in >50% of the mice. Vaccination outcome was critically influenced by the route of vector administration. In CB6F1 mice, vaccination resulted in reduced viremia, delayed onset of splenomegaly, and induction of FV-specific T cells as assessed by tetramer staining. Heterologous prime-boost vaccination resulted in significantly higher neutralizing antibody titers, translating into improved immune protection, in contrast to coexpression of cytokines. Our results suggest that the FV model can provide insight into the development of improved adenovirus vectors for HIV-1 vaccination.
Bayer
Wibke
W
Ruhr-University Bochum, Institute of Microbiology and Hygiene, Department of Molecular and Medical Virology, Building MA, Room 6/40, D-44801 Bochum, Germany.
Schimmer
Simone
S
Hoffmann
Dennis
D
Dittmer
Ulf
U
Wildner
Oliver
O
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D005622:Friend murine leukemia virus / Q000235:genetics* / Q000276:immunology* / Q000302:isolation & purification; D015752:Genes, env; D015750:Genes, gag; D005822:Genetic Vectors; D006801:Humans; D007115:Immunization Schedule; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D051379:Mice; D008810:Mice, Inbred C57BL; D009500:Neutralization Tests; D016865:Reassortant Viruses; D012192:Retroviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D013045:Species Specificity; D013154:Spleen / Q000821:virology; D013601:T-Lymphocytes / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology
D016915:AIDS Vaccines; D000914:Antibodies, Viral; D016207:Cytokines; D019444:Vaccines, DNA